Obiettivo Cancer care will be revolutionized over the next decade by the introduction of novel therapeutics that target the underlying molecular mechanisms of the disease. With the advent of human genetics, a plethora of genes have been correlated with human diseases such as cancer the SNP maps. Since the sequences are now available, the next big challenge is to determine the function of these genes in the context of the entire organism. Genetic animal models have proven to be extremely valuable to elucidate the essential functions of genes in normal physiology and the pathogenesis of disease. Using gene-targeted mice we have previously identified RANKL as a master gene of bone loss in arthritis, osteoporosis, and cancer cell migration and metastases and genes that control heart and kidney function; wound healing; diabetes; or lung injury Our primary goal is to use functional genomics in Drosophila and mice to understand cell transformation, invasion, and cancer metastases of epithelial tumors. The following projects are proposed: 1. Role of the key osteoclast differentiation factors RANKL-RANK and its downstream signalling cascade in the development of breast and prostate cancer. 2. Requirement of osteoclasts for bone metastases and stem cell niches using a new RANKfloxed allele; function of RANKL-RANK in local tumor cell invasion. 3. Role of RANKL-RANK in the central fever response to understand potential implications of future RANKL-RANK directed therapies. 4. Integration of gene targeting in mice with state-of-the art technologies in fly genetics; use of whole genome tissue-specific in vivo RNAi Drosophila libraries to identify essential and novel pathways for cancer pathogenesis using whole genome screens. 5. Role of TSPAN6, as a candidate lung metastasis gene. Identification of new cancer disease genes will allow us to design novel strategies for cancer treatment and will have ultimately impact on the basic understanding of cancer, metastases, and human health. Campo scientifico medical and health sciencesclinical medicineoncologyprostate cancermedical and health sciencesclinical medicinerheumatologymedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesbasic medicinemedical geneticsnatural sciencesbiological sciencesgeneticsgenomes Parole chiave RANKL-RANK breast cancer fever mammary gland biology metastasis osteoclast prostate cancer signal transduction whole genome drosophila genetics Programma(i) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Argomento(i) ERC-AG-LS4 - ERC Advanced Grant - Physiology, Pathophysiology and Endocrinology Invito a presentare proposte ERC-2008-AdG Vedi altri progetti per questo bando Meccanismo di finanziamento ERC-AG - ERC Advanced Grant Istituzione ospitante INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH Contributo UE € 2 499 465,00 Indirizzo DR BOHRGASSE 3 1030 Wien Austria Mostra sulla mappa Regione Ostösterreich Wien Wien Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Tanja Winkler (Ms.) Ricercatore principale Josef Martin Penninger (Prof.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato Beneficiari (1) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH Austria Contributo UE € 2 499 465,00 Indirizzo DR BOHRGASSE 3 1030 Wien Mostra sulla mappa Regione Ostösterreich Wien Wien Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Contatto amministrativo Tanja Winkler (Ms.) Ricercatore principale Josef Martin Penninger (Prof.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato
